OBJECTIVES: The United Kingdom (UK) runs a successful human papillomavirus (HPV) girls vaccination programme. Debate is ongoing on the value of including boys in the programme. This study aims at quantifying the potential value associated with genital warts (GW) and HPV-related cancer prevention in UK males and females based on a willingness-to-pay threshold of £20,000 per quality-adjusted life-years (QALY) gained, representing the potential value a government places on the prevention of these diseases. METHODS: A static vaccine steady-state (VSS) population model, stratified by age, with a 1-year time horizon, replicated the incidence of GW and HPV-related cancers in females (cervical(CC), anal(AC), vulvar(VuC), vaginal(VaC), oropharyngeal(OP)) and males (penile(PC), AC and OP) pre-vaccination and at VSS. Data were retrieved from UK cancer registries, sexually transmitted diseases reports and HPVCentre. Costs and utilities were identified from the literature. The VSS vaccine effectiveness for GW and HPVrelated cancers was estimated combining efficacies (AS04-adjuvanted HPV-16/18 vaccine for cancers; HPV- 6/11/16/18 vaccine for GW) weighted by vaccine-types (HPV-6/11/16/18) and non-vaccine types (HPV-31/33/35/39/45/51/52/56/58/59) HPV distribution. Costs and QALYs were discounted at 1.5%. Per-course vaccine cost-effective price (vCE-p) was determined by increasing vaccine course price until £20 000per incremental QALY gained at VSS was reached. Sensitivity analyses on key variables were performed. RESULTS: The vCE-p in women (men) was: CC £898, OP £19 (£56), AC £120 (£75), VaC £36, VuC £56, (PC £39), GW £26 (£27). Total value of cancer prevention in women (men) was £1 131 (£169), a proportion of 6.7. The value of CC alone is 5.3 times larger than the total value of cancer prevention in men. Sensitivity analyses showed results were robust while influenced by potential herd protection. CONCLUSIONS: The vCE-p was estimated to be up to 7 times higher in women than in men due to the higher burden and frequency of HPV-related cancers in women.